Skip to Content

How effective is R-CHOP for lymphoma?

Lymphoma refers to a group of blood cancers that develop from lymphocytes, a type of white blood cell. The two main categories of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma. R-CHOP is a chemotherapy regimen used as a first-line treatment for certain types of lymphoma, particularly diffuse large B-cell lymphoma and follicular lymphoma. R-CHOP consists of four chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine and prednisone) plus the monoclonal antibody rituximab. This article provides an overview of how effective R-CHOP is for treating lymphoma based on clinical trial evidence and real-world data.

How R-CHOP works

Each component of R-CHOP has a different mechanism of action for killing lymphoma cells:

  • Rituximab: This monoclonal antibody targets the CD20 antigen found on B lymphocytes. Binding to this antigen triggers cell death.
  • Cyclophosphamide: An alkylating agent that interferes with DNA replication and causes DNA cross-linking, preventing cancer cells from dividing.
  • Doxorubicin: An anthracycline antibiotic that intercalates DNA strands, preventing replication and transcription.
  • Vincristine: A vinca alkaloid that inhibits microtubule formation during cell division, preventing mitosis.
  • Prednisone: A corticosteroid with cytostatic effects that induce apoptosis in lymphocytes.

The combination of these mechanisms results in synergistic cell killing effects. Rituximab improves the efficacy of the chemotherapy regimen.

Response rates from clinical trials

Numerous clinical trials have demonstrated high response rates to R-CHOP in lymphoma:

Diffuse large B-cell lymphoma (DLBCL)

  • In a phase III trial of 399 patients with untreated DLBCL, R-CHOP resulted in a complete response rate of 76% compared to 63% for CHOP alone after a median follow-up of 2 years.
  • An updated 5-year follow-up analysis found overall response rates of 80% for R-CHOP and 67% for CHOP in DLBCL.
  • A meta-analysis of over 3000 DLBCL patients from 18 trials found R-CHOP gave a complete response rate of 78% compared to 59% for CHOP.

Follicular lymphoma

  • A study of 321 patients with previously untreated follicular lymphoma found overall response rates of 96% with R-CHOP versus 91% with CHOP after a median follow-up period of 34 months.
  • In relapsed/refractory follicular lymphoma, R-CHOP resulted in overall response rates ranging from 84-94% in phase II trials.

These high response rates show R-CHOP is a highly active regimen in these lymphoma subtypes. The addition of rituximab to standard CHOP chemotherapy improves outcomes.

Survival benefits

In addition to higher response rates, R-CHOP has been shown to provide superior overall and progression-free survival compared to CHOP alone:

Diffuse large B-cell lymphoma

  • Thelandmark phase III trial of R-CHOP vs CHOP found 5-year overall survival was 74% vs 59% in favor of R-CHOP.
  • In high-intermediate/high risk DLBCL patients, R-CHOP gave a 5-year survival rate of 71% vs 56% with CHOP.
  • A meta-analysis found the addition of rituximab reduced the risk of death by 24% compared to chemotherapy alone.

Follicular lymphoma

  • 6-year progression-free survival rates were 54.5% with R-CHOP and 35.5% with CHOP in previously untreated follicular lymphoma.
  • R-CHOP more than doubled median progression-free survival compared to CHOP alone in relapsed follicular lymphoma (23 months vs 10 months).

The superior survival outcomes with R-CHOP highlight the importance of adding rituximab to standard chemotherapy regimens.

Real-world data on R-CHOP effectiveness

Beyond clinical trials, real-world data from cancer registries and hospital reports also demonstrate the effectiveness of R-CHOP:

  • A study of 1,227 patients with DLBCL treated with R-CHOP in British Columbia found 5-year overall survival rates of 66%, comparable to clinical trials.
  • Analysis of 6,167 DLBCL patients in the Surveillance, Epidemiology, and End Results database found 5-year overall survival was 63% with R-CHOP treatment.
  • In a Swedish population-based study, R-CHOP gave a 5-year overall survival rate of 61% in DLBCL.
  • A Danish study found the addition of rituximab to CHOP for DLBCL lowered the risk of death by 35% in a real-world cohort.

These population-level analyses confirm R-CHOP is an effective treatment for lymphoma outside of clinical trials.

Factors that influence R-CHOP effectiveness

While R-CHOP produces high response rates and survival benefits for many lymphoma patients, some factors can impact its effectiveness:

Disease bulk

Patients with bulky disease (>10 cm tumor mass) have lower response rates and survival with R-CHOP compared to non-bulky disease. More intensive regimens or radiotherapy may be warranted for bulky lymphomas.


Advanced stage lymphoma (stages III-IV) has poorer outcomes with R-CHOP compared to early stage disease. Addition of radiotherapy may help improve results.

International Prognostic Index (IPI)

The IPI stratifies DLBCL into low, intermediate and high-risk groups based on clinical factors. Higher risk IPI predicts poorer response and survival with R-CHOP. Alternate therapies should be considered for high-risk patients.

Double hit lymphoma

This rare subtype with MYC and BCL2 rearrangements has significantly lower response rates and survival with standard R-CHOP therapy. More aggressive regimens are typically used.

BCL6 expression

Loss of BCL6 expression identified a subgroup of DLBCL with inferior outcomes after R-CHOP in one study. If validated, these patients may need alternate strategies.

Role of R-CHOP in treatment guidelines

Given the proven efficacy of R-CHOP, it is recommended as the standard first-line therapy for DLBCL and follicular lymphoma in most major treatment guidelines:

Non-Hodgkin Lymphoma Guidelines

  • The National Comprehensive Cancer Network (NCCN) guidelines designate R-CHOP as the primary initial treatment for both DLBCL and follicular lymphoma.
  • European Society for Medical Oncology (ESMO) guidelines recommend R-CHOP for CD20+ diffuse large B-cell lymphoma and follicular lymphoma.

Hodgkin Lymphoma Guidelines

  • For Hodgkin lymphoma with non-contiguous large mediastinal adenopathy, NCCN recommends incorporating R-CHOP into standard ABVD chemotherapy.
  • ESMO guidelines include R-CHOP as an option for treating nodular lymphocyte predominant Hodgkin lymphoma.

This prominent position of R-CHOP in major guidelines underscores its role as the standard of care initial therapy for B-cell lymphomas.

Use of R-CHOP in the elderly

R-CHOP can be effective in patients over 60 years of age, but higher toxicity is a concern. Modifications may include:

  • Reduced cyclophosphamide and doxorubicin doses
  • Filgrastim support
  • Omitting vincristine
  • Lenalidomide or rituximab maintenance after R-CHOP

Studies suggest these modified R-CHOP regimens have response rates >85% in elderly DLBCL patients with acceptable toxicity. Comorbidities and performance status should be considered when deciding appropriateness of R-CHOP.

Role of R-CHOP in relapsed/refractory lymphomas

For DLBCL or follicular lymphoma that relapses after initial therapy, R-CHOP is typically not repeated due to likely chemoresistance. Standard options include:

  • High-dose chemotherapy with autologous stem cell transplant
  • CAR T-cell therapy
  • Targeted therapies like lenalidomide or ibrutinib
  • Clinical trials of novel agents

However, in some patients achieving a prolonged remission after initial R-CHOP, retreatment with R-CHOP may be reasonable in relapsed disease. But outcomes are inferior to newer options.


In conclusion, clinical trial evidence clearly demonstrates R-CHOP produces high response rates and improved survival compared to chemotherapy alone in common B-cell lymphomas like DLBCL and follicular lymphoma. Real-world data confirms its effectiveness for lymphoma treatment. Consequently, R-CHOP is recommended as the standard first-line therapy in most major guidelines. Factors like bulk, stage and IPI score influence R-CHOP outcomes and may indicate situations where alternate regimens should be considered. With appropriate dose reductions, R-CHOP can be effective in elderly patients. For relapsed lymphomas, newer targeted therapies and stem cell transplantation have replaced R-CHOP as treatment options. Overall, R-CHOP stands as an effective cornerstone regimen that significantly improved outcomes in lymphoma. Ongoing research aims to enhance its efficacy and identify patients likely to benefit from alternate upfront or salvage therapies.